CoChat

Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence

Open access
Xu, Ying, Su, Guan-Hua, Ma, Ding, Xiao, Yi, Shao, Zhi-Ming, Jiang, Yi-Zhou · 2021 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.

Abstract

Immunotherapies play critical roles in cancer treatment. However, given that only a few patients respond to immune checkpoint blockades and other immunotherapeutic strategies, more novel technologies are needed to decipher the complicated interplay between tumor cells and the components of the tumor immune microenvironment (TIME). Tumor immunomics refers to the integrated study of the TIME using immunogenomics, immunoproteomics, immune-bioinformatics, and other multi-omics data reflecting the immune states of tumors, which has relied on the rapid development of next-generation sequencing. High-throughput genomic and transcriptomic data may be utilized for calculating the abundance of immune cells and predicting tumor antigens, referring to immunogenomics. However, as bulk sequencing represents the average characteristics of a heterogeneous cell population, it fails to distinguish distinct cell subtypes. Single-cell-based technologies enable better dissection of the TIME through precise immune cell subpopulation and spatial architecture investigations. In addition, radiomics and digital pathology-based deep learning models largely contribute to research on cancer immunity. These artificial intelligence technologies have performed well in predicting response to immunotherapy, with profound significance in cancer therapy. In this review, we briefly summarize conventional and state-of-the-art technologies in the field of immunogenomics, single-cell and artificial intelligence, and present prospects for future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00729-7

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Components and interactions of the tumor immune microenvironment. a Cellular compositions of the tumor immune microenvironment. b Brief illustration of cell–cell interaction in anti-tumor immunity. cDC conventional dendritic cells, CTL cytotoxic T lymphocyte, Gzm granzyme, IFN interferon, MHC major histocompatibility complex, NK cells natural killer cells, pDC plasmacytoid dendritic cells, PFN perforin, TCR T cell receptor, Th T helper cell, TNF tumor necrosis factor
Fig. 1 Components and interactions of the tumor immune microenvironment. a Cellular compositions of the tumor immune microenvironment. b Brief illustration of cell–cell interaction in anti-tumor immunity. cDC conventional dendritic cells, CTL cytotoxic T lymphocyte, Gzm granzyme, IFN interferon, MHC major histocompatibility complex, NK cells natural killer cells, pDC plasmacytoid dendritic cells, PFN perforin, TCR T cell receptor, Th T helper cell, TNF tumor necrosis factorCC BY · PubMed Central
Fig. 2 Development of single-cell spatial technologies: from germination to maturity. (1) Initiation stage: H&E staining, a conventional but significant method that clearly demonstrates the cellular and tissue structure but underperforms in the discrimination of immune cells. (2) Growing stage: The specific binding of antibodies and antigens drove the spatial technologies to a new height as represented by IHC and IF. In addition, multiplex IHC/IF technologies allow the detection of multiple markers simultaneously on a single slice, improving our understanding of the TIME spatial architecture. (3) Mature stage: Given that the spectral overlap limits the further application of mIHC/IF, utilizing dye cycling is a main optimization strategy in which only two or three antibodies are imaged by fluorescence microscopy in each cycle. Then, the fluorophores are cleaved and washed, and this cycle is repeated until all antibodies are imaged, such as CODEX, MxIF, and MELC. Also, IMC and MIBI-TOF utilize mental-conjugated antibodies to eliminate confounding factors, such as spectral overlap, and are also promising. (4) Postmature stage: Combining high-resolution spatial information with single-cell expression data, spatial transcriptomics, slide-seq, HDST, etc. explore brand-new ideas for the characterization of the spatial architecture. CODEX codetection by indexing, HDST high-definition spatial transcriptome, H&E hematoxylin-eosin, IF immunofluorescence, IHC immunohistochemistry, IMC imaging mass cytometry, MELC multiepitope ligand cartography, MIBI-TOF multiplexed ion beam imaging by time-of-flight, MxIF multiplexed fluorescence microscopy method
Fig. 2 Development of single-cell spatial technologies: from germination to maturity. (1) Initiation stage: H&E staining, a conventional but significant method that clearly demonstrates the cellular and tissue structure but underperforms in the discrimination of immune cells. (2) Growing stage: The specific binding of antibodies and antigens drove the spatial technologies to a new height as represented by IHC and IF. In addition, multiplex IHC/IF technologies allow the detection of multiple markers simultaneously on a single slice, improving our understanding of the TIME spatial architecture. (3) Mature stage: Given that the spectral overlap limits the further application of mIHC/IF, utilizing dye cycling is a main optimization strategy in which only two or three antibodies are imaged by fluorescence microscopy in each cycle. Then, the fluorophores are cleaved and washed, and this cycle is repeated until all antibodies are imaged, such as CODEX, MxIF, and MELC. Also, IMC and MIBI-TOF utilize mental-conjugated antibodies to eliminate confounding factors, such as spectral overlap, and are also promising. (4) Postmature stage: Combining high-resolution spatial information with single-cell expression data, spatial transcriptomics, slide-seq, HDST, etc. explore brand-new ideas for the characterization of the spatial architecture. CODEX codetection by indexing, HDST high-definition spatial transcriptome, H&E hematoxylin-eosin, IF immunofluorescence, IHC immunohistochemistry, IMC imaging mass cytometry, MELC multiepitope ligand cartography, MIBI-TOF multiplexed ion beam imaging by time-of-flight, MxIF multiplexed fluorescence microscopy methodCC BY · PubMed Central
Fig. 3 Radiomics and computational pathology in tumor immunity exploration. Radiological and pathological image-derived omics data enable the investigation of the tumor immune microenvironment (TIME) and response to immunotherapy. For a raw radiology image, regions of interest, generally representing the tumor lesion area, are segmented, while a pathological image is divided into numerous sub-images. Two methods can be applied to analyze these high-dimensional data. First, features, including but not limited to statistical features, tumor volume features, and texture features, are extracted and analyzed by professional clinicians. Alternatively, images are input into a convolutional neural network (CNN). After a complicated deep learning process, robust models are output. These radiomics or digital pathologic models could finally be established to evaluate or predict the immune index, which can be divided into three aspects. First, TIME dissection encompasses distinct immune cell subset classification and TIME spatial architecture characterization, resembling single-cell technologies and CODEX, respectively. Second, immune-related biomarkers, such as the tumor mutation burden (TMB), could be predicted. Third, response to immunotherapy and clinical outcomes could be predicted. ROI regions of interest, TIME tumor immune microenvironment, TMB tumor mutation burden
Fig. 3 Radiomics and computational pathology in tumor immunity exploration. Radiological and pathological image-derived omics data enable the investigation of the tumor immune microenvironment (TIME) and response to immunotherapy. For a raw radiology image, regions of interest, generally representing the tumor lesion area, are segmented, while a pathological image is divided into numerous sub-images. Two methods can be applied to analyze these high-dimensional data. First, features, including but not limited to statistical features, tumor volume features, and texture features, are extracted and analyzed by professional clinicians. Alternatively, images are input into a convolutional neural network (CNN). After a complicated deep learning process, robust models are output. These radiomics or digital pathologic models could finally be established to evaluate or predict the immune index, which can be divided into three aspects. First, TIME dissection encompasses distinct immune cell subset classification and TIME spatial architecture characterization, resembling single-cell technologies and CODEX, respectively. Second, immune-related biomarkers, such as the tumor mutation burden (TMB), could be predicted. Third, response to immunotherapy and clinical outcomes could be predicted. ROI regions of interest, TIME tumor immune microenvironment, TMB tumor mutation burdenCC BY · PubMed Central
Fig. 4 A landscape of immunomics: developmental tendency and future direction. a The timeline of immunomics technologies. b Historical development trajectory and future prospective of tumor immunomics. CODEX codetection by indexing, CyTOF cytometry by time-of-light, ESTIMATE estimation of stromal and immune cells in malignant tumors using expression data, GATK Genome Analysis Toolkit, GenomeVIP Genome Variant Investigation Platform, HDST high-definition spatial transcriptome, IMC imaging mass cytometry, MCP-counter microenvironment cell populations-counter, MIBI-TOF multiplexed ion beam imaging by time-of-flight, mIF multiplex immunofluorescence, mIHC multiplex immunohistochemistry
Fig. 4 A landscape of immunomics: developmental tendency and future direction. a The timeline of immunomics technologies. b Historical development trajectory and future prospective of tumor immunomics. CODEX codetection by indexing, CyTOF cytometry by time-of-light, ESTIMATE estimation of stromal and immune cells in malignant tumors using expression data, GATK Genome Analysis Toolkit, GenomeVIP Genome Variant Investigation Platform, HDST high-definition spatial transcriptome, IMC imaging mass cytometry, MCP-counter microenvironment cell populations-counter, MIBI-TOF multiplexed ion beam imaging by time-of-flight, mIF multiplex immunofluorescence, mIHC multiplex immunohistochemistryCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–303 of 303

Cited by

See all 169

Metadata

Authors
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Xiao, Yi
  • Shao, Zhi-Ming
  • Jiang, Yi-Zhou
Venue
Signal Transduction and Targeted Therapy
Published
2021-08-20
Volume
6
Issue
1
Pages
312-312
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3194492341
Cited by
163
References
303
Citations by year
2026: 18 · 2025: 36 · 2024: 38 · 2023: 50 · 2022: 16 · 2021: 5
FWCI
3.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81874113, 82002792, 81922048, 81874112)
  • Fok Ying Tong Education Foundation (171034)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cancer immunotherapy, tumor immune microenvironment, immunogenomics, immunoproteomics, single-cell analysis, artificial intelligence, radiomics, digital pathology, deep learning, immune checkpoint blockade, immunotherapy response prediction, tumor heterogeneity, immune cell subpopulations
MeSH terms
Antigens, Neoplasm, Artificial Intelligence, Humans, Immunity, Innate, Immunogenetics, Immunotherapy, Neoplasms, Biomarkers, Tumor, Genome, Human, Cell Lineage, Proteome, Single-Cell Analysis, Tumor Microenvironment, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.